Defence Therapeutics Inc. DTCFF
0.26 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.2101 Day range 0.2593
0.1906 52-week range 0.759
- YTD
- -53.50%
- 1 year
- -54.51%
- Market cap
- 19.73M
- EPS (ttm)
- -0.08
- YTD return
- -53.50%
- 1-year return
- -54.51%
- Volume
- 7.60K
- Avg volume
- 10.38K
- Open
- 0.2101
- Previous close
- 0.2593
- Day's range
- 0.2101 – 0.2593
- 52-week range
- 0.1906 – 0.759
2Y -0.1546 (-37.35%)
News
Defence Therapeutics Announces Convertible Debenture Interest Payment 
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform 
Defence Therapeutics Inc. (OTCMKTS:DTCFF) Stock Short Interest Report for September 
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates 
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors 
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities 
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders 
Defence Therapeutics Provides Updates on Sharing Agreement 
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs 
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Your note
Sign in to keep a note on DTCFF — it syncs with the Stock Master app.